US regulators approved an HIV drug described as a “miracle” by the UN for its ability to prevent infections with two doses a year.
When given to people at risk of HIV in the US and Africa, Gilead’s lenacapavir vastly outperformed the standard pre-exposure prophylaxis drug, which requires…